Zydus and Guardant Health to jointly promote genomic tests for solid cancers

Guardant360 is a minimally invasive liquid biopsy test that provides comprehensive genomic profiling (CGP) of all solid tumours by analysing circulating tumour DNA (ctDNA) from a simple blood draw

Zydus Lifesciences and Guardant Health have signed a co-marketing agreement to jointly promote the Guardant360® portfolio of liquid and tissue biopsy tests across India and Nepal. The tests to be promoted include the Guardant360 nd Guardant360 TissueNext tests for comprehensive genomic profiling and the Guardant360 Response test for monitoring response to treatment.

The agreement aims to advance precision medicine and improve patient outcomes in the region.

For doctors treating patients with advanced cancer, the Guardant360 portfolio of tests provides a complete tumour genomic view at every step of the treatment journey, offering insights to help them quickly start patients on the optimal treatment based on their tumour genomic profile, and to monitor response to that treatment. Guardant360 is a minimally invasive liquid biopsy test that provides comprehensive genomic profiling (CGP) of all solid tumours by analysing circulating tumour DNA (ctDNA) from a simple blood draw.

Guardant360 TissueNext provides CGP results from a tumour tissue biopsy to give doctors actionable information when tissue testing is appropriate. Guardant360 Response is a monitoring test that allows oncologists to track a patient’s treatment response over time.